StocktoriaHCW Biologics Inc. HCWB
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $54,232 | $2.6M | $2.8M | $6.7M | $0 |
| Gross profit | $10,846 | $959,403 | $560,360 | $2.6M | $0 |
| Operating income | -$13.2M | -$29.5M | -$25.7M | -$15.1M | -$13.4M |
| Net income | -$8.0M | -$30.0M | -$25.0M | -$14.9M | -$12.9M |
| Operating cash flow | -$13.4M | -$14.2M | -$22.5M | -$10.4M | -$11.0M |
| Free cash flow | -$13.4M | -$14.5M | -$28.7M | -$20.7M | -$11.0M |
| Total assets | $24.5M | $30.2M | $28.5M | $46.8M | $53.5M |
| Total liabilities | $21.8M | $37.0M | $15.1M | $9.4M | $2.3M |
| Shareholders' equity | $2.8M | -$6.8M | $13.5M | $37.4M | $51.2M |
| Ratios | |||||
| Gross margin | 20.0% | 37.4% | 19.7% | 38.5% | — |
| Operating margin | -24270.7% | -1147.6% | -905.0% | -224.3% | — |
| Net margin | -14677.1% | -1169.7% | -879.5% | -221.7% | — |
| FCF margin | -24693.2% | -564.5% | -1010.5% | -307.4% | — |
| Return on assets | -32.5% | -99.3% | -87.7% | -31.8% | -24.0% |
| Return on equity | -287.9% | 443.5% | -185.7% | -39.8% | -25.1% |
| Debt / equity | 0.00× | -1.09× | 0.47× | 0.17× | 0.00× |
| Current ratio | 0.11 | 0.19 | 0.73 | 11.52 | 17.44 |
| Revenue growth | -97.9% | -9.7% | -57.7% | — | -100.0% |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001828673 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.